Histopathological changes in bone marrow biopsies from patients with chronic myeloid leukaemia after treatment with recombinant alpha-interferon

被引:21
作者
Facchetti, F
Tironi, A
Marocolo, D
Capucci, A
Ruggeri, G
Bellotti, D
Rossi, G
机构
[1] UNIV BRESCIA, DEPT CLIN CHEM, I-25124 BRESCIA, ITALY
[2] UNIV BRESCIA, DEPT GENET, I-25124 BRESCIA, ITALY
[3] UNIV BRESCIA, DEPT INTERNAL MED 3 HEMATOL, I-25124 BRESCIA, ITALY
关键词
chronic myeloid leukaemia; alpha-interferon; bone marrow; histology;
D O I
10.1046/j.1365-2559.1997.5700796.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: Recombinant alpha-interferon (r-IFN) is an effective therapy for chronic myeloid leukaemia (CML), inducing haematological and major cytogenetic response in 70% and 30% of patients, respectively, In this study we have evaluated the significance of bone marrow (BM) histology on the subsequent response to r-IFN therapy as well as the morphological changes induced by r-IFN within BM, Methods and Results: 73 BM biopsies were studied from 21 patients with Ph-1-positive CML in chronic phase at diagnosis and at different times during r-IFN treatment, At diagnosis the probability of achieving a major or complete cytogenetic response was significantly higher in patients with a total marrow cellularity lower than 90% (P=0.02), During therapy with r-IFN, significant BM changes included disappearance of the CML pattern (P=0.0002), reduction of M:E ratio (P=0,0009) and total cellularity (P=0,0027), and increase in number of terminal megakaryocytes (P=0.0009) and of fatty tissue regeneration (P=0,037); only after long-term therapy (mean 20 months), did reticulin fibrosis increase significantly (P=0.032), Conclusions: The overall BM morphology in response to treatment displayed different pictures, ranging from persistence of CML (25 biopsies out of 51.), to reversion to normal histology (14 out of 51), Persistence of diffuse morphological abnormalities was associated with lack of cytogenetic responsiveness (P=0.025).
引用
收藏
页码:3 / 11
页数:9
相关论文
共 42 条
[21]  
GRIFFIN CG, 1990, EXP HEMATOL, V18, P1013
[22]  
GRONTHOS S, 1992, LEUKEMIA, V6, P1246
[23]   RANDOMIZED COMPARISON OF INTERFERON-ALPHA WITH BUSULFAN AND HYDROXYUREA IN CHRONIC MYELOGENOUS LEUKEMIA [J].
HEHLMANN, R ;
HEIMPEL, H ;
HASFORD, J ;
KOLB, HJ ;
PRALLE, H ;
HOSSFELD, DK ;
QUEISSER, W ;
LOFFLER, H ;
HOCHHAUS, A ;
HEINZE, B ;
GEORGII, A ;
BARTRAM, CR ;
GRIESSHAMMER, M ;
BERGMANN, L ;
ESSERS, U ;
FALGE, C ;
QUEISSER, U ;
MEYER, P ;
SCHMITZ, N ;
EIMERMACHER, H ;
WALTHER, F ;
FETT, W ;
KLEEBERG, UR ;
KABISCH, A ;
NERL, C ;
ZIMMERMANN, R ;
MEURET, G ;
TICHELLI, A ;
KANZ, L ;
TIGGES, FJ ;
SCHMID, L ;
BROCKHAUS, W ;
TOBLER, A ;
REITER, A ;
PERKER, M ;
EMMERICH, B ;
VERPOORT, K ;
ZANKOVICH, R ;
VONWUSSOW, P ;
PRUMMER, O ;
THIELE, J ;
BUHR, T ;
CARBONELL, F ;
ANSARI, H .
BLOOD, 1994, 84 (12) :4064-4077
[24]   HISTOLOGICAL STUDY OF BONE-MARROW REGENERATION FOLLOWING CHEMOTHERAPY FOR ACUTE MYELOID-LEUKEMIA AND CHRONIC GRANULOCYTIC-LEUKEMIA IN BLAST-TRANSFORMATION [J].
ISLAM, A ;
CATOVSKY, D ;
GALTON, DAG .
BRITISH JOURNAL OF HAEMATOLOGY, 1980, 45 (04) :535-&
[25]  
*IT COOP STUD GROU, 1993, LEUKEMIA LYMPHOMA, V11, P67
[26]  
KANTARJIAN HM, 1993, BLOOD, V82, P691
[27]  
KURZROCK R, 1988, NEW ENGL J MED, V319, P990
[28]  
LAUGHLIN M, 1988, BLOOD, V72, P936
[29]   DETECTION OF RESIDUAL BCR/ABL TRANSCRIPTS IN CHRONIC MYELOID-LEUKEMIA PATIENTS IN COMPLETE REMISSION USING THE POLYMERASE CHAIN-REACTION AND NESTED PRIMERS [J].
MARTIAT, P ;
MAISIN, D ;
PHILIPPE, M ;
FERRANT, A ;
MICHAUX, JL ;
CASSIMAN, JJ ;
VANDENBERGHE, H ;
SOKAL, G .
BRITISH JOURNAL OF HAEMATOLOGY, 1990, 75 (03) :355-358
[30]  
OSTERHOLZ J, 1991, EXP HEMATOL, V19, P326